ONCOLOGY Vol 26 No 12 | Oncology

"Come Home": A Medicare Innovation Center Project

December 19, 2012

The Come Home project will demonstrate that community oncology practices can aggressively manage the symptoms and complications of cancer and its treatment-and at the same time can save money by limiting the use of expensive sites of service like hospitals and emergency departments.

A New Look at an Old Syndrome

December 19, 2012

The current standard therapies for chronic lymphocytic leukemia do not prevent Richter's transformation from occurring. If we are fortunate, new treatments will realize the hope that this usually fatal complication of chronic lymphocytic leukemia might be avoided.

Richter's Syndrome: CLL Taking a Turn for the Worse

December 19, 2012

Early results suggest that the new targeted therapies for CLL may have a profound impact on survival-and thus on the incidence of Richter's transformation. It will therefore become increasingly important to study Richter's transformation more assiduously, to diagnose it sooner, and to develop strategies to treat this extremely challenging entity.

Clinicopathologic Indices Can Improve Patient Selection in Malignant Mesothelioma

December 18, 2012

The clinical management of malignant mesothelioma may ultimately be transformed by the elucidation of novel biomarkers that can predict the evolution of disease and guide the development of targeted therapies. However, despite relevant advances, more basic research is urgently required to support the development of therapies applicable to the patients for whom surgical resection is not an option.

Clinical and Pathological Features Are Still the Best Determinants of Prognosis in Mesothelioma

December 18, 2012

Significant advances have been made in our understanding of the factors affecting the prognosis of malignant mesothelioma, and a number of biomarkers appear promising. However, at present it may be more fruitful to better define and characterize clinical factors that are well recognized as significantly impacting patient survival.

The Important Role of Secondary Treatment in Hodgkin Lymphoma

December 18, 2012

It is time to move on to next key steps of improving recognition of treatment-resistant lymphoma at diagnosis, rather than at treatment failure, by optimally employing biomarkers and improving cure rates by integrating powerful but minimally toxic new systemic agents into primary treatment.

Treatment for Favorable Localized Hodgkin Lymphoma: the Final Answer Is Awaited

December 18, 2012

The likelihood that combined-modality therapy will provide a small progression-free survival advantage is real but not likely to be equated to an overall survival advantage, as it depends on when one looks at the data. The studies to date demonstrate a late fall-off in survival due to one or another toxic effect of radiation.

Prostate Cancer 2012: Where Do We Stand and Where Are We Heading?

December 19, 2012

Recent progress in our understanding of the pathogenesis of advanced prostate cancer has heralded a new era in treatment. Numerous agents now populate the treatment landscape, and an impressive number of novel agents are in development. However, many questions remain unanswered, paving the path for discovery in the future.

Prostate Cancer: What Did We Learn From the 2012 Annual Scientific Meeting of ASCO?

December 19, 2012

This review summarizes recent findings in clinical prostate cancer research reported at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology (ASCO) and addresses their relevance to clinical practice.

Combined-Modality Therapy for Early-Stage Hodgkin Lymphoma: Maintaining High Cure Rates While Minimizing Risks

December 18, 2012

In Hodgkin lymphoma, as with many other malignancies, a combined-modality approach has proven successful. This tactic capitalizes on the relative advantages of both modalities, yet minimizes risk by avoiding intense exposure to either. This article will summarize the data supporting this approach in early-stage Hodgkin lymphoma.

Richter's Transformation in Chronic Lymphocytic Leukemia

December 19, 2012

Richter's transformation, or Richter's syndrome, is an uncommon clinicopathological condition observed in about 5% to 10% of patients with chronic lymphocytic leukemia (CLL). This review summarizes advances in our understanding of the pathobiology and in the management of Richter's transformation in patients with CLL.